These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 1310497

  • 1. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
    Coleman CN, Buswell L, Noll L, Riese N, Rose MA.
    Int J Radiat Oncol Biol Phys; 1992; 22(3):565-8. PubMed ID: 1310497
    [Abstract] [Full Text] [Related]

  • 2. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
    Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Noll L, Hancock S, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial.
    Riese NE, Buswell L, Noll L, Pajak TF, Stetz J, Lee DJ, Coleman CN.
    Int J Radiat Oncol Biol Phys; 1997 Nov 01; 39(4):855-8. PubMed ID: 9369134
    [Abstract] [Full Text] [Related]

  • 4. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
    Coleman CN, Noll L, Riese N, Buswell L, Howes AE, Loeffler JS, Alexander E, Wen P, Harris JR, Kramer RA.
    Int J Radiat Oncol Biol Phys; 1992 Nov 01; 22(3):577-80. PubMed ID: 1531217
    [Abstract] [Full Text] [Related]

  • 5. Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).
    Lawton CA, Coleman CN, Buzydlowski JW, Forman JD, Marcial VA, DelRowe JD, Rotman M.
    Int J Radiat Oncol Biol Phys; 1996 Oct 01; 36(3):673-80. PubMed ID: 8948352
    [Abstract] [Full Text] [Related]

  • 6. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Bleehen NM, Newman HF, Maughan TS, Workman P.
    Int J Radiat Oncol Biol Phys; 1989 Apr 01; 16(4):1093-6. PubMed ID: 2539346
    [Abstract] [Full Text] [Related]

  • 7. The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.
    Bleehen NM, Maughan TS, Workman P, Newman HF, Stenning S, Ward R.
    Radiother Oncol; 1991 Apr 01; 20 Suppl 1():137-42. PubMed ID: 1826962
    [Abstract] [Full Text] [Related]

  • 8. Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.
    Lee DJ, Phillips TL, Coleman CN, Cosmatos D, Davis LW, Wasserman TH, Marcial VA, Rubin P.
    Int J Radiat Oncol Biol Phys; 1992 Apr 01; 22(3):569-71. PubMed ID: 1531215
    [Abstract] [Full Text] [Related]

  • 9. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
    Urtasun RC, Palmer M, Kinney B, Belch A, Hewitt J, Hanson J.
    Int J Radiat Oncol Biol Phys; 1998 Jan 15; 40(2):337-42. PubMed ID: 9457818
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer.
    Beard C, Buswell L, Rose MA, Noll L, Johnson D, Coleman CN.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):611-6. PubMed ID: 7516321
    [Abstract] [Full Text] [Related]

  • 11. Progress report of a phase II and a phase III trial with etanidazole (SR-2508): a multicentre European study.
    Chassagne D, Sancho-Garnier H, Charreau I, Eschwege F, Malaise EP.
    Radiother Oncol; 1991 Jun 15; 20 Suppl 1():121-7. PubMed ID: 1826960
    [Abstract] [Full Text] [Related]

  • 12. Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.
    Workman P, Ward R, Maughan TS, Newman HF, Bleehen NM.
    Int J Radiat Oncol Biol Phys; 1989 Jul 15; 17(1):177-81. PubMed ID: 2526107
    [Abstract] [Full Text] [Related]

  • 13. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Newman HF, Ward R, Workman P, Bleehen NM.
    Int J Radiat Oncol Biol Phys; 1988 Nov 15; 15(5):1073-83. PubMed ID: 2972667
    [Abstract] [Full Text] [Related]

  • 14. First analysis of tumor regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas.
    Chassagne D, Charreau I, Sancho-Garnier H, Eschwege F, Malaise EP.
    Int J Radiat Oncol Biol Phys; 1992 Nov 15; 22(3):581-4. PubMed ID: 1531218
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
    Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Hirst VK, Hancock S, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1986 Jul 15; 12(7):1105-8. PubMed ID: 3017904
    [Abstract] [Full Text] [Related]

  • 16. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN, Halsey J, Cox RS, Hirst VK, Blaschke T, Howes AE, Wasserman TH, Urtasun RC, Pajak T, Hancock S.
    Cancer Res; 1987 Jan 01; 47(1):319-22. PubMed ID: 3024818
    [Abstract] [Full Text] [Related]

  • 17. Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours.
    Bornstein BA, Herman TS, Hansen JL, Buswell L, Zouranjian PS, Fraser SM, Teicher BA, Svensson GK, Coleman CN.
    Int J Hyperthermia; 1995 Jan 01; 11(4):489-99. PubMed ID: 7594803
    [Abstract] [Full Text] [Related]

  • 18. Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
    Buswell L, Recht A, Clark J, Ravikumar T, Busse PM, Coleman CN.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):535-40. PubMed ID: 8005812
    [Abstract] [Full Text] [Related]

  • 19. Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
    Coleman CN, Noll L, Howes AE, Harris JR, Zakar J, Kramer RA.
    Int J Radiat Oncol Biol Phys; 1989 Apr 15; 16(4):1085-7. PubMed ID: 2522919
    [Abstract] [Full Text] [Related]

  • 20. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
    Coleman CN, Urtasun RC, Wasserman TH, Hancock S, Harris JW, Halsey J, Hirst VK.
    Int J Radiat Oncol Biol Phys; 1984 Sep 15; 10(9):1749-53. PubMed ID: 6237086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.